- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | H.C. Wainwright senkt Kursziel für Vor Biopharma auf 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 15.04. | H.C. Wainwright lowers Vor Biopharma price target to $31 | 1 | Investing.com | ||
| 08.04. | Stifel reiterates Vor Biopharma stock rating on drug potential | 1 | Investing.com | ||
| 08.04. | Stifel bekräftigt Kaufempfehlung für Vor Biopharma wegen Medikamentenpotenzial | 1 | Investing.com Deutsch | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 01.04. | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 30.03. | Stifel cuts Vor Biopharma stock price target on financing assumptions | 2 | Investing.com | ||
| 30.03. | Stifel senkt Kursziel für Vor Biopharma aufgrund neuer Finanzierungsannahmen | 2 | Investing.com Deutsch | ||
| 30.03. | Vor Biopharma reports Q4 results | 2 | Seeking Alpha | ||
| 30.03. | Vor Bio doses first patient in phase 3 Sjögren's disease trial | 1 | Investing.com | ||
| 30.03. | Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 234 | GlobeNewswire (Europe) | First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept... ► Artikel lesen | |
| 30.03. | Vor Biopharma: Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease | 232 | GlobeNewswire (Europe) | BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first... ► Artikel lesen | |
| 30.03. | Vor Biopharma Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Vor Biopharma Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 29.03. | Jefferies startet Vor Biopharma mit Kaufempfehlung nach strategischer Neuausrichtung | 6 | Investing.com Deutsch | ||
| 29.03. | Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot | 1 | Investing.com | ||
| 27.03. | Vor Bio raises $75M in private placement led by TCGX | 1 | Investing.com | ||
| 27.03. | Vor Bio announces $75M private placement | 2 | Seeking Alpha | ||
| 27.03. | Vor Biopharma: Vor Bio Announces $75 Million Private Placement with TCGX | 2 | GlobeNewswire (USA) | ||
| 27.03. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.03. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 43,400 | +4,25 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| EDITAS MEDICINE | 2,470 | -0,40 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| GERON | 1,337 | +4,05 % | Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | CSE Bulletin: Suspension - SOL Global Investments Corp. (SOL) | Le 7 avril/April 2026
Effective immediately, SOL Global Investments Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,168 | +2,55 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| TRINITY BIOTECH | 0,642 | -3,46 % | Trinity Biotech plc: Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture Prostate Cancer Test | Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,600 | +1,53 % | Cathie Wood's ARK sells Nvidia stock, buys Arcturus Therapeutics | ||
| OVID THERAPEUTICS | 2,300 | +2,68 % | H.C. Wainwright bestätigt Kaufempfehlung für Ovid Therapeutics | ||
| CERVOMED | 3,120 | -1,89 % | CervoMed Inc. - 8-K, Current Report | ||
| EQUILLIUM | 1,880 | +2,17 % | Oppenheimer initiates Equillium stock with Outperform on UC drug | ||
| CABALETTA BIO | 2,940 | -3,61 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| 4D MOLECULAR THERAPEUTICS | 9,405 | -2,13 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 27,280 | -3,64 % | VinFast, Alcoa, And Regencell Are Among the Top 10 Large-Cap Gainers Last Week (March 30-April 2): Are the Others in Your Portfolio? | ||
| THX PHARMA | 3,335 | +0,60 % | THERANEXUS: THX Pharma Announces the Publication of its Letter to Shareholders | Lyon, France - March 25, 2026, 6:30 pm CET - THX Pharma (Theranexus), an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of... ► Artikel lesen | |
| LONGEVERON | 0,961 | -1,63 % | Longeveron Announces 2025 Full Year Financial Results and Provides Business Update | On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,54 % bei einem Aktienkurs von 13,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.